Cytotoxic chemotherapeutic agents often induce a cluster of cancer treatment related symptoms (CTRS). The purpose of this study was to develop a mouse model of CTRS to examine the role of IL-1b and TNF-a signaling in the genesis of these symptoms. CTRS (change in wheel running activity, food intake, and body weight from baseline) were examined in wild type (WT) mice or mice lacking the TNF-a p55 (type 1) receptor (TNFR1À/À) and/or IL-1b type 1 receptor (IL-1R1À/À) injected with four doses of cyclophosphamide/Adriamycin/5-fluorouracil (CAF) at 20-day intervals. Inflammatory cytokines in blood and tissues were measured using multiplex immunoassays and quantitative RT-PCR. ANOVA was used to examine differences between genotype and/or treatment group. Kaplan-Meier analysis was used to estimate survival rate. CAF rapidly increased IL-1b and TNF-a signaling in WT mice. CAF induced acute CTRS immediately following drug injection which returned to baseline prior to the next CAF dose. Persistent CTRS were evident 3 weeks after the 4th CAF dose. Acute but not persistent CTRS were associated with increased levels of IL-7, IL-9, KC, MCP-1, GCSF, and IP-10. This CAF induced inflammatory response was blunted in IL-1R1 deficient mice and absent in IL-1R1/TNFR1-deficient mice. IL-1R1À/À mice showed an identical pattern of CTRS to their WT counterparts. The assessment of CTRS in IL-1R1/TNF-R1-deficient mice was precluded by severe toxicity. Our data suggest that an important function of the IL-1b and TNFa driven inflammatory cascade is to promote recovery following exposure to cytotoxic agents.
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Background
Cancer patients undergoing treatment with cytotoxic chemotherapy often experience a cluster of symptoms including fatigue, loss of appetite (anorexia), sleep disturbance, pain, and cognitive dysfunction, which can have profound negative effects on physical functioning and quality of life during and after treatment (Berger et al., 2012; Oh and Seo, 2011) . Cancer treatment related symptoms (CTRS) typically occur in the days following chemotherapy infusion (de Jong et al., 2005 (de Jong et al., , 2006a . In approximately large proportion of cancer survivors, CTRS, most notably fatigue, can persist for months or years after cytotoxic chemotherapy has ended (Bower et al., 2006) . The etiological mechanisms underlying CTRS are unclear. It has long been suspected, however, that CTRS are homologous to sickness behavior, a physiological response to activation of the innate immune system triggered by increased production and synergistic action of the pro-inflammatory cytokines interleukin 1 beta (IL-1b) and tumor necrosis factor alpha (TNFa) (Dantzer et al., 2012; Wood and Weymann, 2013; Bluthe et al., 2000) .
IL-1b and TNF-a are produced by macrophages, monocytes and other cells of the innate immune system in response harmful stimuli such as cytotoxic agents. Cytotoxic chemotherapy kills tumor cells but also healthy cells in the hematopoietic and gastrointestinal systems. The intracellular components liberated from these dying cells act as ''Danger Signals'' which prime resident tissue macrophages via activation of their surface Toll-Like-Receptors (TLRs) (Bianchi, 2007) . In addition, priming of these cells via TLR activation also occurs following bacterial translocation (passage of bacteria or bacterial products i.e. endotoxin, across the intestinal mucosal barrier) related to chemotherapy induced gastrointestinal damage (Cerci et al., 2007; Tsuji et al., 2003) . In addition to these indirect effects, cytotoxic chemotherapy directly increase the
